For the Inventor, By the Inventor

Enter assignee name

Freiburg, Germany

Dr. Falk Pharma Gmbh

USPTO Granted Patents = 32

CIPO Patents = 2

EPO Patents = 14

Trademarks = 3

Forward Citations = 354

Loading Chart...

Loading Chart...

38 inventors (with patents filed for the assignee):

Rudolf Wilhelm (11 out of 11 patents)

Roland Greinwald (10 out of 10 patents)

Norbert Otterbeck (10 out of 10 patents)

4. Markus Proels (6 out of 6 patents)

5. Markus Pröls (6 out of 6 patents)

6. Ralph Mueller (4 out of 4 patents)

7. Peter Gruber (4 out of 13 patents)

8. Rudolph Wilhelm (3 out of 3 patents)

9. Ralf Mohrbacher (3 out of 3 patents)

10. Tanju Nacak (2 out of 2 patents)

11. Mark Renshaw (2 out of 10 patents)

12. Erik Fischer (2 out of 2 patents)

13. Heidi Waenerlund Poulsen (2 out of 2 patents)

14. Yoji Yamada (2 out of 5 patents)

15. Jessie-Farah Fecteau (2 out of 4 patents)

32 patents: Sort by Forward Citations

1. 12516126 - ANTI-CD30L ANTIBODIES AND USES THEREOF (2026-01-06),

2. 12472191 - Pharmaceutical formulation for the treatment of inflammatory changes to the rectum (2025-11-18),

3. 12459906 - 3-(5-chloro-2-oxobenzo[d]oxazol-3(2H)-yl) propanoic acid derivatives as KMO inhibitors (2025-11-04),

4. 12064509 - Enema for rectal application (2024-08-20),

5. 11866505 - Anti-CD30L antibodies and uses thereof (2024-01-09),

6. 11850252 - Use of nor-ursodeoxycholic acid for reducing liver fat (2023-12-26),

7. 11738032 - Pharmaceutical formulation for the treatment of inflammatory changes to the rectum (2023-08-29),

8. 11464733 - Enema for rectal application (2022-10-11),

9. 11382860 - Optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus (2022-07-12),

10. 11173121 - Pellets having a multi-layer structure for delayed release of the active substance in the distal colon (2021-11-16),

11. 11135159 - Optimized high-dose mesalazine-containing tablet (2021-10-05),

12. 10905699 - Pharmaceutical formulation for the treatment of inflammatory changes to the rectum (2021-02-02),

13. 10695291 - Optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus (2020-06-30),

14. 10369100 - Optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus (2019-08-06),

15. 10000526 - Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size (2018-06-19),

Dr. Falk Pharma GmbH is a pharmaceutical company dedicated to providing innovative solutions for gastrointestinal and liver diseases. With a focus on research, development, and production, we strive to improve the lives of patients worldwide through effective and safe medications. Our team of experts collaborates with healthcare professionals to ensure the highest quality products and comprehensive patient care. Visit our website to learn more about our company, products, and commitment to healthcare.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 6 2026

32 Patents

#13 in Freiburg

#1,557 in Germany

#20,109 in the World

Freiburg, Germany

Dr. Falk Pharma Gmbh

Forward Citations = 354

38 inventors:

Rudolf Wilhelm (11 out of 11 patents)

Roland Greinwald (10 out of 10 patents)

Norbert Otterbeck (10 out of 10 patents)

4. Markus Proels (6 out of 6 patents)

5. Markus Pröls (6 out of 6 patents)

Please report any incorrect information to support@idiyas.com

Loading…